New treatments for venous thromboembolic disease

被引:2
作者
Combe, S. [1 ]
机构
[1] Grp Hosp Cochin Broca Hotel Dieu, F-75679 Paris 14, France
关键词
Venous thromboembolism; Therapy;
D O I
10.1016/S0398-0499(11)70003-8
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Following the landmark study by Barritt and Jordan in 1960, in which patients with venous thromboembolism (VTE) were randomized to no treatment or a combination of heparin and warfarin, antithrombotic therapy for this disease became widely accepted. This study was stopped prematurely because half of the non-treated patients had recurrent pulmonary embolism (PE), or died. It was subsequently found that after a VTE, patients given warfarin alone had a 3-4-fold higher incidence of recurrent VTE than patients given both heparin and warfarin. Since the 1990s, standard therapy for VTE has comprised an initial 5-7 day course of parenteral anticoagulant plus warfarin continued for at least 3 months. Recently, several orally active small molecules have been evaluated in the treatment of VTE, including a direct thrombin inhibitor and direct Factor Xa inhibitors. Other novel oral agents are also in development for VTE treatment. Although the DTI ximelagatran, the first oral agent to be introduced since warfarin was withdrawn from the market in Europe because of hepatotoxicity, evidence from clinical trial evaluating other single target-specific oral agents in the treatment of VTE is encouraging. It is therefore likely that use of warfarin in the treatment and secondary prevention of VTE will decrease should these novel oral agents be introduced for these indications. Additionally, there will be less distinction between initial and long-term therapy, and a great majority of patients will be treated on an outpatient basis for prolonged periods of time. Recently these expectations were fulfilled by the results of two Phase III studies in patients with VTE. The Recover I study indicated that Dabigatran (150mg b.d.) following an initial course of LMWH was non-inferior to the standard treatment of LMWH plus warfarin, with also a similar safety profile. The Einstein DVT study revealed that Rivaroxaban as a single agent can safely replace the standard treatment in patients with DVT. Taken together these studies and a few others that have or are about to be completed will indeed introduce a paradigm shift in the way patients with VTE will be treated. (C) 2011 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:S16 / S19
页数:4
相关论文
共 50 条
[41]   Mean platelet volume as a prognostic factor for venous thromboembolic disease [J].
Manuel Diaz, Juan ;
Boietti, Bruno R. ;
Vazquez, Fernando J. ;
Waisman, Gabriel D. ;
Giunta, Diego H. ;
Paloma Rojas, Liliana ;
Peuchot, Veronica ;
Lourdes Posadas-Martinez, Maria .
REVISTA MEDICA DE CHILE, 2019, 147 (02) :145-152
[42]   Periodontal disease as a risk factor of recurrence of venous thromboembolic disease: a prospective study [J].
Sanchez-Siles, Mariano ;
Rosa-Salazar, Vladimir ;
Salazar-Sanchez, Noemi ;
Camacho-Alonso, Fabio .
ACTA ODONTOLOGICA SCANDINAVICA, 2015, 73 (01) :8-13
[43]   Adverse outcomes in patients with venous thromboembolic disease from a rural population [J].
Calvo-Romero, Jose Maria ;
Lima-Rodriguez, Esther Maria .
SOUTHERN MEDICAL JOURNAL, 2008, 101 (06) :601-603
[44]   Internal jugular vein thrombosis, an atypical location of venous thromboembolic disease [J].
Fuentes Spinola, Maria ;
Criado-Garcia, Juan ;
Limia Perez, Laura .
MEDICINA CLINICA, 2017, 149 (10) :459-460
[45]   Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management [J].
Donnellan, E. ;
Kevane, B. ;
Bird, B. R. Healey ;
Ainle, F. Ni .
CURRENT ONCOLOGY, 2014, 21 (03) :134-143
[46]   Risk Assessment Scores for Cancer-Associated Venous Thromboembolic Disease [J].
Angelini, Dana ;
Khorana, Alok A. .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2017, 43 (05) :469-478
[47]   Prophylaxis of venous thromboembolic disease in high-risk orthopedic surgery [J].
Meza Reyes, Gilberto Eduardo ;
Esquivel Gomez, Ricardo ;
del Campo Sanchez, Antonio Martinez ;
Espinosa-Larranaga, Francisco ;
Enrique Martinez Guzman, Miguel Angel ;
Torres Gonzalez, Ruben ;
de la Fuente Zuno, Juan Carlos ;
Mendez Huerta, Juan Vicente ;
Villalobos Garduno, Enrique ;
Cymet Ramirez, Jose ;
Ibarra Hirales, Efren ;
Diaz Borjon, Efrain ;
Aguilera Zepeda, Jose Manuel ;
Valles Figueroa, Juan Francisco ;
Majluf-Cruz, Abraham .
GACETA MEDICA DE MEXICO, 2012, 148 (02) :144-152
[48]   Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns [J].
Keramidas, George ;
Gourgoulianis, Konstantinos I. ;
Kotsiou, Ourania S. .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (10)
[49]   Venous Thromboembolic Disease in COVID-19, Pathophysiology, Therapy and Prophylaxis [J].
Dybowska, Malgorzata ;
Wyrostkiewicz, Dorota ;
Opoka, Lucyna ;
Lewandowska, Katarzyna ;
Sobiecka, Malgorzata ;
Tomkowski, Witold ;
Szturmowicz, Monika .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
[50]   Venous thromboembolic disease in admitted blunt trauma patients: what matters? [J].
Lineberry, Camille ;
Alexis, Dimitri ;
Mukhi, Ambika ;
Duh, Kevin ;
Tharakan, Mathew ;
Vosswinkel, James A. ;
Jawa, Randeep S. .
THROMBOSIS JOURNAL, 2023, 21 (01)